Activating Compound | Comment | Organism | Structure |
---|---|---|---|
dibutyryl-cGMP | activates E20M activity by 50fold, diminished by injections of guanylate cyclase inhibitors alone or combined with ecdysone agonist RH-5849 | Manduca sexta | |
additional information | no activation by dibutyryl cAMP, cGMP, or cAMP | Manduca sexta |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1H-[1,2,4]oxadizolo[4,3-a]-quinoxalin-1-one | a guanylate cyclase inhibitor, applied with ecdysone agonist RH-5849 results in 63% reduced E20M activity | Manduca sexta | |
6-anilinoquinoline-5,6-quinone | LY-38583, a guanylate cyclase inhibitor, applied with ecdysone agonist RH-5849 results in 80% reduced E20M activity, addition of guanylate cyclase activator S levels the activity to 78% of control activity | Manduca sexta | |
methylene blue | a guanylate cyclase inhibitor, applied with ecdysone agonist RH-5849 results in 86% reduced E20M activity, reversed by addition of dibutyryl-cGMP/theophylline to 87% of control activity | Manduca sexta | |
additional information | inhibitory effects of guanylate cyclase inhibitors with RH-5849 in vivo, overview | Manduca sexta |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Manduca sexta | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
larva | during the last larval stadium of the midgut, E20M activity increases 50fold coincident with wandering onset | Manduca sexta | - |
midgut | during the last larval stadium of the midgut, E20M activity increases 50fold coincident with wandering onset | Manduca sexta | - |
Synonyms | Comment | Organism |
---|---|---|
E20M | - |
Manduca sexta |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.5 | - |
assay at | Manduca sexta |